Abstract：
Integrase inhibitors and tenofovir alafenamide have become a mainstay in modern antiretroviral therapy; more recently, they have been implicated as causing increased weight gain beyond what may be expected with the \"return to health\" phenomenon. Some patients, namely those assigned female at birth, of the black race, or with lower baseline CD4 counts, may be more likely to experience weight gain. This review outlines existing evidence linking the agents to excessive weight as well as ongoing efforts to combat these effects.
摘要：
整合酶抑制剂和替诺福韦艾拉酚胺已成为现代抗逆转录病毒疗法的支柱;最近,它们被认为导致体重增加，超出了“恢复健康”现象的预期。有些病人,即出生时被分配给女性的人，黑人种族，或基线CD4计数较低，可能更有可能经历体重增加。这篇综述概述了将这些药物与超重联系起来的现有证据，以及为对抗这些影响所做的持续努力。
